Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Technology
ALLISON GATLIN

AstraZeneca Expects Flat 2022 Covid Sales — Which Is Better Than Expected

AstraZeneca raised its 2022 sales outlook after its Covid treatment, Evusheld, made an unexpectedly hefty contribution to second-quarter sales — but AZN stock inched lower Friday.

Evusheld is an antibody treatment that helps protect against Covid in immunocompromised people. During the June quarter, Evusheld generated $914 million in sales. That was 22% above Wall Street's forecasts, SVB Securities analyst Andrew Berens said.

Meanwhile, AstraZeneca's Covid vaccine — which is not authorized in the U.S., but is used abroad — brought in $1.54 billion in sales, growing 36% on a strict, as-reported basis.

The performance of the two products, in addition to its underlying business, pushed AstraZeneca to raise its sales outlook. Now, the company expects full-year sales to increase by the low 20% range, up from its prior view for that was in the high-teens. AstraZeneca also predicted growth in a range of mid-to-high 20 percentage points in core earnings.

On the stock market today, AZN stock dipped a fraction to close at 66.23.

AZN Stock: Flat Covid Sales In 2022

Despite the increase in total sales guidance, AstraZeneca expects flat sales of Covid drugs overall for 2022. Previously, the company called for a decline. But growth in Evusheld is expected to offset a decline for its Covid vaccine, Vaxzevria. Pfizer and Moderna are also struggling with slowing demand for their Covid shots.

Overall, AstraZeneca's sales climbed 31% to $10.77 billion, topping projections for $10.33 billion, according to FactSet. Core earnings surged 92% to $1.72 per share and also beat expectations.

Berens, the SVB analyst, noted cancer drugs Calquence and Imfinzi beat expectations. AstraZeneca also reported better-than-expected sales of diabetes drug Farxiga, a rare disease medicine called Soliris, acid reflux treatment Nexium and cholesterol med Crestor.

He kept his outperform rating on AZN stock.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.